Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
August 20, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for May 16, 2005 Subscribe to this News Feed      
 

Alzheimer's Disease Drug Market to Exceed $5 Billion by 2009

Currently more than 10% of Americans age 65 or older suffer from Alzheimers disease.

(PRWEB) May 16, 2005 -- Alzheimers is a degenerative disease that will affect 10 million people in the G7 countries by 2009. Currently more than 10% of Americans age 65 or older suffer from Alzheimers disease (AD), of which only a quarter receive AD drug medications. The advent of new drugs has revolutionized AD care. According to Millennium Research Groups new Global Markets for Alzheimers Disease Medications 2005, the market for AD drug therapy in the US, Europe, and Japan will generate over $3 billion in 2005, with the US accounting for over 60% of market revenues. As aging baby boomers throughout the developed world enter the high-risk years for AD, the market for AD drugs will grow rapidly, reaching $5.5 billion by 2009.

In its new report, Millennium Research Group (MRG) measures the influence of a range of trends and new developments on the use of AD drugs in the US, Europe, and Japan. By separating mild–moderate from moderate–severe indications, and existing treatments from future practices, the report forecasts 15% annual growth over the next five years. In addition to predicting the continued dominance of Eisai (ESALY.PK)/Pfizers (PFE) Aricept, and the strong growth of memantine-based drugs such as Forest Laboratories (FRX) Namenda, other companies covered in the report include: Andrómaco Laboratories, Bracco, First Horizon Pharmaceutical Corp (FHRX), Janssen Pharmaceutica (JNJ), Laboratorios Esteve, Lundbeck (HLUKF.PK), Merz Pharma, Novartis (NVS), OTL Pharma, Shire Pharmaceuticals (SHPGY), and Sigma-Tau Research, Inc.

MRG is a leading player in health care competitive intelligence. With over 50 analysts and researchers, we publish over 80 reports on the global health care market annually.

Contact Information:
Nilesh Patel
Millennium Research Group Inc.,
+1 (416) 364-7776 ext. 121
npatel@mrg.net
www.mrg.net

# # #

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Amy Krohn
MILLENNIUM RESEARCH GROUP
416-364-7776
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright